Table 3 Overall survival and progression- free disease period

Gender

0.122

0.727

0.919

0.338

 Male

62

8.04

6.71–9.38

62

7.19

5.84–8.53

 Female

61

11.12

8.90–13.34

61

10.69

8.44–12.94

Age

7.493

0.006

2.775

0.096

 <55

56

13.56

11.68–15.44

56

11.55

9.42–13.69

 ≥55

66

7.06

5.47–8.64

66

7.06

5.47–8.64

Site

2.887

0.089

1.202

0.273

 GIH

80

7.94

6.58–9.29

80

7.59

6.24–8.94

 Pancreas

43

12.53

10.14–14.93

43

10.88

8.42-13.35

Tumour Grading

 G1

106

11.57

9.93–13.22

11.869

0.001

106

10.69

9.04–12.34

15.232

<0.001

 G2 or G3

14

3.28

1.37–5.18

14

2.86

1.26–4.45

Size

2.632

0.105

4.660

0.031

 <2cm

67

12.31

10.11–14.51

67

11.82

9.63–14.01

 ≥2cm

44

8.61

6.75–10.48

44

7.51

5.68–9.34

Chromogranin A Staining

0.119

0.730

0.347

0.556

 Positive

107

10.86

9.16–12.55

107

10.03

8.35–11.70

 Negative

16

7.81

4.46–11.17

16

6.93

3.71–10.14

Functionality

2.915

0.088

2.315

0.128

 Non- functional

113

8.69

7.48–9.90

113

8.04

6.83–9.24

 Functional

10

15.36

12.24–18.49

10

13.92

10.11–17.73

Metastases on Presentation

44.760

<0.001

41.259

<0.001

 Yes

26

3.39

1.83–4.94

26

3.18

1.74–4.61

 No

96

12.29

11.60–14.98

96

12.23

10.47–13.98